Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IL-15 armored glypican-3–specific CAR-T cells for solid tumors, including hepatocellular carcinoma and several pediatric sarcomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embryonal Sarcoma of the Liver
• Hepatocellular Carcinoma
• Liposarcoma
• Malignant Rhabdoid Tumor
• Rhabdomyosarcoma
• Wilms Tumor
• Yolk Sac Tumor

Drugs mentioned

• GPC3-IL-15 Armored CAR-T

Snippet

Sponsor: Baylor College of Medicine | Conditions: Liver Cell Carcinoma, Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING